FDA Approves Genentech's Itovebi For Advanced Breast Cancer With PIK3CA Mutation
11/10 03:05
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), said that the U.S. Food and Drug Administration approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone rece...